LifeMD (LFMD) Liabilities and Shareholders Equity (2012 - 2025)

LifeMD has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $70.4 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 7.47% year-over-year to $70.4 million; the trailing twelve-month figure through Mar 2026 stood at $210.0 million (down 26.61% YoY), and the FY2025 full-year result was $70.4 million, down 7.47% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $70.4 million, up from $66.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $76.1 million in Q4 2024, with the low at $16.4 million in Q3 2021.
• Historically, Liabilities and Shareholders Equity has averaged $47.9 million across 5 years, with a median of $45.3 million in 2021.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 718.13% — and 2022, when it sank 48.59%.
• LifeMD's Liabilities and Shareholders Equity stood at $49.9 million in 2021, then slumped by 48.59% to $25.7 million in 2022, then jumped by 127.85% to $58.5 million in 2023, then jumped by 30.12% to $76.1 million in 2024, then slipped by 7.47% to $70.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $70.4 million (Q4 2025), $66.0 million (Q3 2025), and $73.6 million (Q2 2025), per Business Quant data.